Covaxin may see higher uptake post authorization
Live MintUptake of the domestically developed covid-19 vaccine Covaxin may significantly increase as states that have been cautious about administering it become more confident after a full regulatory emergency licensure is given to it. Bharat Biotech International Ltd, the manufacturer of Covaxin, has submitted its interim data on the vaccine, which showed 81% efficacy, to the Drugs Controller General of India V.G. “It has submitted interim efficacy data to the DCGI and the SEC will soon meet to decide whether to recommend a full emergency use authorization to Covaxin,” the person quoted above said. Experts have said that they are already seeing an increase in registrations for vaccinations at hospitals such as Delhi’s All India Institute of Medical Sciences where Covaxin is being administered after Bharat Biotech last week announced its interim phase 3 trial data that showed the vaccine has an efficacy of 80.6%. The low uptake of Covaxin is primarily on account of some states such as Chhattisgarh being hesitant to use Bharat Biotech’s jabs because of lack of efficacy data earlier.